SBIR-STTR Award

Purification of marine oil derived polyunsaturates
Award last edited on: 12/23/14

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$550,000
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
William R Russo

Company Information

Ocean Organics Inc

One Main Street
Hope , RI 02831
   N/A
   N/A
   N/A
Location: Single
Congr. District: 02
County: Providence

Phase I

Contract Number: 1R43GM036168-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1986
Phase I Amount
$50,000
The specific aim of this project is to develop technologically efficient and cost-effective methods for the separation and purification of multigram quantities of high polyunsaturates (e.g., Eicosapentaenoic Acid, EPA, C20:5w3; Docosahexaenoic Acid, DHA, C22:6w3; and esters) from marine/fish oils, with the long-term objective of making these and possibly other high polyunsaturates available for a waiting marketThe health-relatedness of the proposed project is due to the fact that EPA and DHA are modulators of the biosynthesis of Prostaglandins and other eicosanoids of expanding physiologic and pathophysiologic interest in biology and medicine; affect physical properties of membrane glycerophospholipids; and, in native (Eskimos, certain coastal dwellers) and experimental diets rich in EPA and DHA, have antithrombotic and cardioprotective effects. The methodology for the separation and purification of EPA, DHA, and other marine oil-derived polyunsaturates would focus on state-of-the-art innovations (systems and separation science) in preparative high-performance liquid chromatography.National Institute of General Medical Sciences (NIGMS)

Phase II

Contract Number: 2R44GM036168-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1987
(last award dollars: 1988)
Phase II Amount
$500,000

The specific aim of the proposed project is to develop technologically efficient and cost-effective methods for the separation and purification of multigram quantities of high polyunsaturates (e.g., eicosapentaenoic acid, EPA, C20:5w3; docosahexaenoic acid, DHA, C22:6w3; and esters) from marine/fish oils with the long-term objective of making these and possibly other high polyunsaturates available for a waiting market. The health relatedness of the proposed project is due to the fact that EPA and DHA are modulators of the biosynthesis of prostaglandins and other eicosanoids, of expanding physiologic and pathophysiologic interest in biology and medicine. They affect the physical properties ofmembrane glycerophospholipids, and there is accumulating evidence that native (Eskimos, certain coastal dwellers) and experimental diets rich in EPA and DHA have antithrombotic and cardioprotective effects.The methodology for the separation and purification of EPA, DHA, and other marine oil-derived polyunsaturates will focus on state-of-theart innovations (systems and separation science) in preparative high-performance liquid chromatography. Commercial applications, opportunities, and potential markets will reflect the extensive and prolific research activities and worldwide interest in the leukotriene/lipoxin-precursor polyunsaturated fatty acid cascades and modulation.National Institute of General Medical Sciences (NIGMS)